{"id":25219,"date":"2022-12-26T12:40:10","date_gmt":"2022-12-26T07:10:10","guid":{"rendered":"http:\/\/finservwealth.com\/hetero39s-covid-19-oral-drug-nirmacom-generic-paxlovid-gets-who-prequalification\/"},"modified":"2022-12-26T12:40:10","modified_gmt":"2022-12-26T07:10:10","slug":"hetero39s-covid-19-oral-drug-nirmacom-generic-paxlovid-gets-who-prequalification","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/hetero39s-covid-19-oral-drug-nirmacom-generic-paxlovid-gets-who-prequalification\/","title":{"rendered":"Hetero#39;s COVID-19 oral drug Nirmacom (generic Paxlovid) gets WHO prequalification"},"content":{"rendered":"<p> A press release from the drug maker said it is the first prequalification for a generic version of Pfizer#39;s COVID-19 oral anti-viral drug #39;Paxlovid,#39; which the WHO called, the best therapeutic choice for high-risk patients to date.<\/p><div id=\"finse-3816262702\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/business\/hetero39s-covid-19-oral-drug-nirmacom-(generic-paxlovid)-gets-who-prequalification_16785501.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>A press release from the drug maker said it is the first prequalification for a generic version of Pfizer#39;s COVID-19 oral anti-viral drug #39;Paxlovid,#39; which the WHO called, the best therapeutic choice for high-risk patients to date. Read More<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-25219","post","type-post","status-publish","format-standard","hentry","category-latest-news"],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/25219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=25219"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/25219\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=25219"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=25219"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=25219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}